Author(s):
Amruta Sainath Patil, Amrutkar Sunil V, Nalwade Santaji, Abhijit Bhausaheb Patil
Email(s):
bhadgaleamruta@gmail.com
DOI:
10.52711/0974-360X.2025.00095 
Address:
Amruta Sainath Patil1, Amrutkar Sunil V2, Nalwade Santaji3, Abhijit Bhausaheb Patil4
1M. Pharm (Pharmaceutical Chemistry), Shrimaan Sureshdada Jain College of Pharmacy, Chandwad, Nashik, India.
2M. Pharm, PhD (Pharmaceutical Chemistry), GES’s Sir Dr. M.S. Gosavi College of Pharmaceutical Education and Research, Nashik, India.
3MSc, PhD, Callidus Research Laboratories Pvt. Ltd., 23 PAP- A-29/1, Chakan Industrial Area Phase-IV, Nighoje, Tal-Khed, India.
4M. Pharm, (Pharmaceutical Chemistry)
Callidus Research Laboratories Pvt. Ltd., 23 PAP- A-29/1, Chakan Industrial Area Phase-IV, Nighoje, Tal-Khed, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2025
ABSTRACT:
An entirely new gradient reversed-phase high performance liquid chromatographic technology is used to quantitatively identify empagliflozin and its six process associated contaminants in pharmaceutical dosage forms. With a buffered mobile phase made up of solvent A (orthophosphoric acid 1.0ml diluted with water up to1000mL) and solvent B (a combination of 800:200 v/v ratio of acetonitrile to methanol) delivered with a detection wavelength of 225nm and 1mL/min flow rate, chromatographic separation has been achieved on an Avantor, ACE Excel, 5µm, C18-PFP, 250mm x 4.6 mm. Resolution for every pair of empagliflozin and its six impurities is more than 2.0. The drug was exposed to oxidative, alkaline, hydrolytic, thermal, and photolytic stress conditions. Empagliflozin was observed to deteriorate significantly in the presence of oxidative, acid-base hydrolysis, thermal, and photolytic stress conditions. The method's stability was demonstrated by the distinct separation of the primary peak, its process-related contaminants, and breakdown products. The mass balance for each degradation sample was found to range from 95% to 105% when the samples kept under stress condition were analysed with respect to a standard reference. Therefore, the detection of empagliflozin by assay in pharmaceutical dose forms is suitable with this method of detection. In accordance with ICH requirements, the developed method's linearity, specificity, accuracy, precision, limit of detection, and limit of quantification, were all validated.
Cite this article:
Amruta Sainath Patil, Amrutkar Sunil V, Nalwade Santaji, Abhijit Bhausaheb Patil. A Validated Stability Indicating High Performance Liquid Chromatographic Method for determination of impurities in Empagliflozin Film Coated Tablets. Research Journal of Pharmacy and Technology.2025;18(2):639-6. doi: 10.52711/0974-360X.2025.00095
Cite(Electronic):
Amruta Sainath Patil, Amrutkar Sunil V, Nalwade Santaji, Abhijit Bhausaheb Patil. A Validated Stability Indicating High Performance Liquid Chromatographic Method for determination of impurities in Empagliflozin Film Coated Tablets. Research Journal of Pharmacy and Technology.2025;18(2):639-6. doi: 10.52711/0974-360X.2025.00095 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-2-27
5. REFERENCES:
1. R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D.E. Sharp, R.A. Bakker, M. Mark, T. Klein, P. Eickelmann, Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes Obes. Metab. 2011; Oct. 11; 14 (1): 83–90. https://doi.org/10.1111/j.1463-1326.2011.01517.x
2. J.E. Frampton, Empagliflozin: a review in type 2 diabetes, Drugs. 2018; June; 78 (10): 1037–1048. https://doi.org/10.1007/s40265-018-0937-z.
3. J.R. White, Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus, Ann. Pharmacother. 2015; February; 49 (5): 582–598. https://doi.org/10.1177/1060028015573564.
4. Chen Y, Li H, Hong H, Tao H, Peng X, Xu G. Isolation and characterization of novel process-related impurities in empagliflozin. Journal of Pharmaceutical and Biomedical Analysis. May 2021; 198: 114001. https://doi.org/10.1016/j.jpba.2021.114001.
5. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61(12): 2461–2498. doi:10.1007/s00125-018-4729-5. PMID 30288571.
6. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes (Press release). U.S. Food and Drug Administration (FDA). 6 December 2016. Archived from the original on 11 February 2020. Retrieved 12 December 2016.
7. Donepudi S, Achanta S. Validated HPLC-UV method for simultaneous estimation of linagliptin and empagliflozin in human plasma. International Journal of Applied Pharmaceutics. 2018; 10(3): 56-61. DOI: http://dx.doi.org/10.22159/ijap.2018v10i3.24662
8. Manoel JW, Primieri GB, Bueno LM, Wingert NR, Volpato NM, Garcia CV, Schapoval EE, Steppe M. The application of quality by design in the development of the liquid chromatography method to determine empagliflozin in the presence of its organic impurities. RSC Advances. 2020; 10(12): 7313-20. https://doi.org/10.1039/C9RA08442H
9. Ahmad R, Hailat M, Jaber M, Alkhawaja B, Rasras A, Al-Shdefat RA, Mallah EY, Abu Dayyih W. RP-HPLC method development for simultaneous estimation of empagliflozin, pioglitazone, and metformin in bulk and tablet dosage forms. Acta Pol. Pharm. Drug Res. 2021; May 1; 78: 305-15. DOI: 10.32383/appdr/139635
10. Sushil D. Patil, Sayali K. Chaure, Maswood Ahmed Hafizur Rahman, Prajkta U. Varpe, Sanjay Kshirsagar. Development and Validation of Simple UV- Spectrophotometric Method for the Determination of Empagliflozin. Asian J. Pharm. Ana. 2017; 7(1): 18-22.
11. T. Naga Ravi Kiran, P. Parvathi, J.N. Suresh Kumar. Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Linagliptin, Empagliflozin and Metformin in Solid Dosage Forms. Asian J. Pharm. Ana. 2020; 10(3): 117-124.
12. Sushil D. Patil, Sunil V. Amurutkar, C.D. Upasani. Development and Validation of Stability Indicating RP-HPLC Method for Empagliflozin. Asian J. Pharm. Ana. 2016; 6(4): 201-206.
13. Ceema Mathew, Sunayana Varma. Green Analytical Methods based on Chemometrics and UV spectroscopy for the simultaneous estimation of Empagliflozin and Linagliptin. Asian Journal of Pharmaceutical Analysis. 2022; 12(1):43-8.
14. M. M. Eswarudu, G. Ouchitya, N. Sudhakar Reddy, M. Deekshitha, P. Srinivasa Babu. Review on Analytical Methods for Estimation of Antidiabetic Drugs: Empagliflozin, Linagliptin and Metformin Hydrochloride. Asian Journal of Pharmaceutical Analysis. 2023; 13(1): 42-6.
15. Varaprasad, J., Nagendra, K.P.V., Srinivasu, P., Ramaprasad, L.A. and Nagaraju, D. A novel stability-indicating RP-UPLC method for the quantification of impurities and a new QDA mass detector coupled with LC-PDA for identification of mass of degradation products in a fixed dose combination of empagliflozin and linagliptin tablets used as second-line therapy for type-2 diabetes. Int. Res. J. Pharm. 2018; 9(7): 192-201.
16. Mabrouk MM, Soliman SM, El-Agizy HM, Mansour FR. A UPLC/DAD method for simultaneous determination of empagliflozin and three related substances in spiked human plasma. BMC Chemistry. 2019; Dec; 13: 1-9. https://doi.org/10.1186/s13065-019-0604-9
17. Shirisha V, Bolle K, Santosh I, Rao KN, Rajeswar DK. A new simple method development, validation and forced degradation studies of empagliflozin by using RP-HPLC. International Journal of Pharmacy and Biological Sciences. 2019; 9(1): 25-35.
18. Borman P, Elder D. Q2 (R1) validation of analytical procedures: text and methodology. ICH Quality Guidelines: an Implementation Guide. 2017; Sep 27: 127-66. https://doi.org/10.1002/9781118971147.ch5
19. Rignall A. ICH Q1A (R2) stability testing of new drug substance and product and ICH Q1C stability testing of new dosage forms. ICH Quality Guidelines: An Implementation Guide. 2017; Sep 27: 3-44. https://doi.org/10.1002/9781118971147.ch1
20. L. Satyanarayana, S.V. Naidu, M. Narasimha Rao, C. Ayyanna, Alok Kumar. The Estimation of Raltigravir in Tablet dosage form by RP-HPLC. Asian J. Pharm. Ana. 2011; 1(3): July-Sept. 56-58.
21. Mahmoud M. Sebaiy, Abdullah A. El-Shanawany, Sobhy M. El-Adl, Lobna M. Abdel-Aziz, Hisham A. Hashem. Rapid RP-HPLC Method for Simultaneous Estimation of Norfloxacin and Tinidazole in Tablet Dosage Form. Asian J. Pharm. Ana. 2011; 1(4): 79-84.
22. G. Raveendra Babu, J. Srinivasa Rao, K. Suresh kumar, P. Jayachandra Reddy. Stability Indicating Liquid Chromatographic Method for Aripiprazole. Asian J. Pharm. Ana. 2011; 1(1): Jan.-Mar. 03-07.
23. Swati Rawat, Akhilesh Gupta. Regulatory Requirements for Drug Development and Approval in United States: A Review. Asian J. Pharm. Res. 2011; 1(1): Jan.-Mar. 01-06.
24. A.B. Roge, P.S. Tarte, M.M. Kumare, G.R. Shendarkar, S.M. Vadvalkar. Forced Degradation Study: An Important Tool in Drug Development. Asian J. Pharm. Res. 2013; 3(4): 198-201.
25. ICH Q1A (R2). Stability testing of new drug substances and products. In International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2003.
26. ICH Validation of Analytical Procedures: Text and Methodology Q2 (R1), International Conference on Harmonization. 2005.